Explore how neoantigen-based vaccines are revolutionizing cancer immunotherapy by enabling personalized, targeted treatment strategies for better outcomes.
Geneos Therapeutics, a clinical-stage biotech company, a spin-out of Inovio Pharmaceuticals, announced the first cancer patient was dosed using the company's GT-EPIC Neoantigen-Targeting Personalized Vaccine Technology.